In a groundbreaking revelation at the Mobile World Congress in Barcelona, Demis Hassabis, the CEO of Google DeepMind, foresees artificial intelligence (AI) taking the lead in designing drugs directly within clinical settings within the next couple of years. DeepMind, renowned for its cutting-edge AI research, particularly its Alphafold system, which predicts protein structures, stands poised
